An Open-label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib, Cyclophosphamide, and Dexamethasone (ICd) in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM)

被引：2
|
作者：
Dimopoulos, Meletios [1 ]
Grosicki, Sebastian [2 ]
Jedrzejczak, Wieslaw [3 ]
Nahi, Hareth [4 ]
Gruber, Astrid [4 ]
Hansson, Markus [5 ]
Byrne, Catriona [6 ]
Labotka, Richard [6 ]
Teng, Zhaoyang [6 ]
Yang, Huyuan [6 ]
Grzasko, Norbert [7 ,8 ]
Kumar, Shaji [9 ]
机构：
[1] Natl & Kapodistrian Univ Athens, Athens, Greece
[2] Silesian Med Univ Katowice, Katowice, Poland
[3] Med Univ Warsaw, Warsaw, Poland
[4] Karolinska Univ Hosp, Stockholm, Sweden
[5] Skane Univ Hosp, Lund, Sweden
[6] Millennium Pharmaceut Inc, Cambridge, MA USA
[7] Med Univ Lublin, Lublin, Poland
[8] St Johns Canc Ctr, Lublin, Poland
[9] Mayo Clin, Rochester, MN USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷
关键词：
D O I：
10.1016/j.clml.2017.07.148
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MM-135
引用
收藏
页码：S333 / S334
页数：2
相关论文
共 50 条
  • [21] Safety and clinical activity of belantamab mafodotin plus lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: The phase 1/2, prospective, open-label, BelaRd study
    Terpos, Evangelos
    Gavriatopoulou, Maria
    Ntanasis-Stathopoulos, Ioannis
    Malandrakis, Panagiotis
    Fotiou, Despina
    Migkou, Magdalini
    Theodorakakou, Foteini
    Spiliopoulou, Vasiliki
    Syrigou, Rodanthi
    Papaiakovou, Evangelos Eleutherakis
    Gkolfinopoulos, Stavros
    Manousou, Kyriaki
    Kastritis, Efstathios
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)
    Boccia, Ralph V.
    Bessudo, Alberto
    Agajanian, Richy
    Conkling, Paul
    Harb, Wael
    Yang, Hui
    Pinchasik, Dawn
    Kimball, Amy S.
    Berenson, James R.
    BLOOD, 2016, 128 (22)
  • [23] A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)
    Boccia, Ralph V.
    Bessudo, Alberto
    Agajanian, Richy
    Conkling, Paul
    Harb, Wael
    Yang, Hui
    Pinchasik, Dawn
    Kimball, Amy S.
    Berenson, James R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (07): : 433 - 437
  • [24] A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)
    Boccia, Ralph
    Bessudo, Alberto
    Agajanian, Richy
    Conkling, Paul
    Harb, Wael
    Yang, Hui
    Pinchasik, Dawn
    Kimball, Amy
    Berenson, James
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E14 - E14
  • [25] Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study
    Kumar, Shaji K.
    Facon, Thierry
    Usmani, Saad Z.
    Plesner, Torben
    Orlowski, Robert Z.
    Touzeau, Cyrille
    Basu, Supratik
    Bahlis, Nizar J.
    Goldschmidt, Hartmut
    O'Dwyer, Michael E.
    Venner, Christopher P.
    Weisel, Katja
    Hulin, Cyrille
    Karlin, Lionel
    Preis, Meir
    Broyl, Annemiek
    Renwick, William
    Hansson, Markus
    Krevvata, Maria
    Wang, Jianping
    Van Rampelbergh, Rian
    Ukropec, Jon
    Uhlar, Clarissa M.
    Kobos, Rachel
    Perrot, Aurore
    BLOOD, 2020, 136
  • [26] Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial
    Groen, Kaz
    Stege, Claudia A. M.
    Nasserinejad, Kazem
    de Heer, Koen
    van Kampen, Roel J. W.
    Leys, Rineke B. L.
    Thielen, Noortje
    Westerman, Matthijs
    Wu, Ka-Lung
    Ludwig, Inge
    Issa, Djamila E.
    Velders, Gerjo A.
    Vekemans, Marie-Christiane
    Timmers, Gert-Jan
    de Boer, Fransien
    Tick, Lidwine W.
    Verbrugge, Annelies
    Buitenhuis, Danny
    Cunha, Sonia M.
    van der Spek, Ellen
    de Waal, Esther G. M.
    Sohne, Maaike
    Sonneveld, Pieter
    Nijhof, Inger S.
    Klein, Saskia K.
    van der Donk, Niels W. C. J.
    Levin, Mark-David
    Ypma, Paula F.
    Zweegman, Sonja
    ECLINICALMEDICINE, 2023, 63
  • [27] A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma
    O'Donnell, Elizabeth K.
    Laubach, Jacob P.
    Yee, Andrew J.
    Chen, Tianqi
    Huff, Carol Ann
    Basile, Frank G.
    Wade, Philip M.
    Paba-Prada, Claudia E.
    Ghobrial, Irene M.
    Schlossman, Robert L.
    Burke, Jill N.
    Harrington, Cynthia C.
    Lively, Kathleen J.
    Lyons, Hannah F.
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    Trippa, Lorenzo
    Richardson, Paul G.
    Raje, Noopur S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 (02) : 222 - 230
  • [28] Incidence of herpes zoster in transplant-ineligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, and dexamethasone
    Horigome, Yuichi
    Kamata, Hirotoshi
    Michishita, Yusuke
    Yokoyama, Maki
    Tadera, Noriyuki
    Hayama, Kei
    Suzuki, Takahiro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2025,
  • [29] Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: part 1 results of a phase I/II study
    Terpos, Evangelos
    Gavriatopoulou, Maria
    Ntanasis-Stathopoulos, Ioannis
    Malandrakis, Panagiotis
    Fotiou, Despina
    Migkou, Magdalini
    Theodorakakou, Foteini
    Spiliopoulou, Vasiliki
    Kostopoulos, Ioannis V.
    Syrigou, Rodanthi-Eleni
    Eleutherakis-Papaiakovou, Evangelos
    Gkolfinopoulos, Stavros
    Tsitsilonis, Ourania E.
    Kastritis, Efstathios
    Dimopoulos, Meletios A.
    HAEMATOLOGICA, 2024, 109 (08) : 2594 - 2605
  • [30] Real-World Outcomes in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma Treated With Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Lenalidomide/Dexamethasone as Upfront Treatment
    Saeed, Nabiha
    Khan, Zurrya
    Jehanzeb, Hamzah
    Shaikh, Taha
    Shaikh, Usman
    Adil, Salman N.
    Madni, Varisha
    Fatima, Hania
    Abiha, Umm E.
    Ali, Natasha
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (04)
12345